Document is current
Any future updates will be listed below
-
Authors
Burgold, Thomas https://orcid.org/0009-0006-8324-8934
Karakoc, Emre
Gonçalves, Emanuel https://orcid.org/0000-0002-9967-5205
Barrio-Hernandez, Inigo
Dwane, Lisa
Silva, Romina https://orcid.org/0000-0001-5429-0152
Souster, Emily
Sharma, Mamta
Beck, Alexandra
Koh, Gene Ching Chiek https://orcid.org/0000-0002-3840-4954
Zalmas, Lykourgos-Panagiotis
Garnett, Mathew J. https://orcid.org/0000-0002-2618-4237
Bassett, Andrew R. https://orcid.org/0000-0003-1632-9137
-
Funding
Funding for this research was provided by:
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
Wellcome Trust (220540/Z/20/A)
OpenTargets
- License Information
-
More Information
Article History
Received: 23 May 2025
Accepted: 25 November 2025
First Online: 6 December 2025
Competing interests
: A.B. is a founder of and consultant for Ensocell therapeutics. M.G. is a founder of and consultant for Mosaic Therapeutics, receives research funding from GSK and Astex Pharmaceuticals and is a consultant for Bristol-Myers Squibb. The remaining authors declare no competing interests.
